reports
- Research Team ACF
KDST + NLSP Combined Core Investment Case 29052025
We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TDOC TELADOC HEALTH INC.
PODD INSULET CORPORATION
ORMP ORAMED PHARMACEUTICALS
MDT MEDTRONIC PLC
LLY ELI LILLY AND COMPANY
SAN SANOFI
TILS TIZIANA LIFE SCIENCES
CRSP CRISPR THERAPEUTICS AG
SENS SENSEONICS HOLDINGS
TNDM TANDEM DIABETES CARE
NOVO NOVO NORDISK A/S-B
SANA SANA BIOTECHNOLOGY
HIMS HIMS AND HERS HEALTH INC (A)
KDST.TA:TASE KADIMASTEM
NLSP:NasdaqCM NLS PHARMACEUTICS
CRSP (NASDAQ) CRISPR THERAPEUTICS
TLSA TIZIANA LIFE SCIENCES LTD
Eli Lilly & Co: 1 director
A director at Eli Lilly & Co sold 1,000 shares at 716.410USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
- Jonathan Chaplin
A closer look at Cox footprint
We’ve been getting questions from clients about competitive dynamics in Cox’s markets after Charter announced its acquisition. In this note, we use Broadband Insights to explore the fiber competition in Cox’s markets today and in the future, who the largest competitors are, and market demographics.
- Dave Nicoski
- Ross LaDuke
DXCM DEXCOM INC.
XRAY DENTSPLY SIRONA INC.
WING WINGSTOP INC.
VRTS VIRTUS INVESTMENT PARTNERS INC.
UHS UNIVERSAL HEALTH SERVICES INC. CLASS B
STKS ONE GROUP HOSPITALITY
SNPS SYNOPSYS INC.
SMG SCOTTS MIRACLE-GRO COMPANY CLASS A
SFST SOUTHERN FIRST BANCSHARES
RGNX REGENXBIO INC.
RCKY ROCKY BRANDS
PRGO PERRIGO CO. PLC
MPWR MONOLITHIC POWER SYSTEMS INC.
JRVR JAMES RIVER GROUP HOLDINGS LTD
IRM IRON MOUNTAIN INC.
GPC GENUINE PARTS COMPANY
GD GENERAL DYNAMICS CORPORATION
DLTR DOLLAR TREE INC.
DG DOLLAR GENERAL CORPORATION
CROX CROCS INC.
CAL CALERES INC.
BKE BUCKLE INC.
ASC ARDMORE SHIPPING
AMOT ALLIED MOTION TECHNOLOGIES
ACAD ACADIA PHARMACEUTICALS INC.
SBL SAFE BULKERS INC.
LPG DORIAN LPG
MEG. MEG ENERGY CORP.
MDU MDU RESOURCES GROUP INC
NAT NORDIC AMERICAN TANKERS LIMITED
EVTC EVERTEC INC.
FSLR FIRST SOLAR INC.
IONS IONIS PHARMACEUTICALS INC.
NMIH NMI HOLDINGS INC. CLASS A
AGYS AGILYSYS INC.
SJM J.M. SMUCKER COMPANY
FIZZ NATIONAL BEVERAGE CORP.
NHC NATIONAL HEALTHCARE CORP.
INSW INTERNATIONAL SEAWAYS INC.
FLGT FULGENT GENETICS
DK DELEK US HOLDINGS INC
CELH CELSIUS HOLDINGS INC.
AMD ADVANCED MICRO DEVICES INC.
TTEC TTEC HOLDINGS INC.
AVGO BROADCOM INC.
ST SENSATA TECHNOLOGIES HOLDING PLC
ELAN ELANCO ANIMAL HEALTH INC.
MEC MAYVILLE ENGINEERING
DELL DELL TECHNOLOGIES INC CLASS C
CSTM CONSTELLIUM SE CLASS A
OI O-I GLASS INC
BWMN BOWMAN CONSULTING GROUP LTD
DINO HOLLYFRONTIER CORP
EVEX EVE HOLDING INC
SPXC SPX TECHNOLOGIES INC
WEST WESTROCK COFFEE COMPANY LLC
ADCT ADC THERAPEUTICS SA
SVV SAVERS VALUE VILLAGE INC
GUTS FRACTYL HEALTH INC
AGEN AGENUS INC.
ARDT ARDENT HEALTH PARTNERS INC
PCT PROVIDENT CAP TR II SKIS 8.75%29
MKTW MARKETWISE INC
- Jonathan Chaplin
CHTR / Cox: thoughts following the call and detailed deal analysis
We published an initial take yesterday. Blair published his report on regulatory risks to the deal. In this report, we provide quick estimates for synergies, a pro forma model, thoughts on leverage and share repurchases, accretion / dilution, and valuation.
- Blair Levin
- Jonathan Chaplin
Charter Communications Inc: 1 director
A director at Charter Communications Inc sold 215,605 shares at 350.440USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
- Jonathan Chaplin
- Jonathan Chaplin
Autumn for Broadband 1Q25
In this installment of our Autumn for Broadband series, we provide a quick update on trends in the broadband market based on what we have seen from the companies that have reported so far. Net adds declined from an already weak pace a year ago and are well below the pre-pandemic norm. The expected recovery following the end of ACP didn’t materialize. We ponder whether growth is structurally lower, or whether temporary ACP-related pressures have persisted longer than expected.
- Research Team ACF
ACF Thematic Oncology Lung Cancer Cough LCC 25042025
Lung Cancer Cough (LCC) is an under-served, perhaps unserved therapeutic subsegment of the Lung Cancer/Oncology market. 57-65% of early diagnosis lung cancer patients suffer from LCC, it is a highly debilitating condition. The US lung cancer therapeutics market consensus values range from ~USD 29.9bn in 2023 to ~USD 71.3bn in 2034, suggesting a compound annual growth rate (CAGR) of 8.2% over our 10 year forecast period. LCC is a prevalent symptom among lung cancer patients, and its management is...
- Jonathan Chaplin
CHTR and CMCSA: correcting price comparisons
This note corrects the pricing comparison we showed for Comcast and Charter last week. When we checked pricing on the Charter website, we were presented with an old Spectrum One offer, for some reason. In this note, we include a more complete comparison of pricing across both categories of offers available at both companies. The punchline: Charter’s rack rates have come down a lot.
- Jonathan Chaplin
Charter Post-1Q25 Model Update
This note focuses on model changes. Please see separate notes reviewing results and on thoughts following the earnings call. The major changes were higher broadband losses and higher EBITDA in 2025. We expect Consensus to increase broadband losses but also increase EBITDA. Our near-term price target is $448 (+21%). With broadband revaluation and M&A, stock could get to $759 (+105%).
- Jonathan Chaplin
CHTR: quick thoughts following the 1Q25 call
We just wrapped the earnings call (which was brief; efficient). This will be a similarly brief and efficient note that touches on the drivers of the difference in broadband trends between Comcast and Charter, where we think EBITDA growth expectations will go following results, and what it means for repurchases and valuation. We also touch on tariff and macro impact briefly.
- Jonathan Chaplin
CHTR 1Q25 Quick Take: Net adds a little soft; EBITDA beat
Net adds missed estimates, but the miss was less severe than some might have feared following Comcast’s results. Importantly, adds in existing markets improved year-over-year. EBITDA growth was 3.5% after adjusting for a one-time benefit. This was well ahead of expectations. Estimates for EBITDA and FCF will likely increase for the year. Repurchases are back, and the Company seemed to reaffirm a leverage target of 4.25x. Repurchase estimates should increase too with higher EBITDA and FCF.
- Blair Levin
In Good News for CMSCA, DIS (and Robocallers and Pirate Radio, Among O...
What’s New: The Fifth Circuit overturned the FCC’s 2020 and 2024 decisions to impose a $57 million fine against T for actions related to improper use customer data. Based on a recent Supreme Court decision, the appellate court ruled that the FCC actions violate T’s Seventh Amendment right to a jury trial, likely upending broader FCC enforcement efforts. In this note we analyze the impact of the Court’s decision on our coverage universe generally and well as specifically to some of the companie...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
DLTR DOLLAR TREE INC.
CVGW CALAVO GROWERS INC.
CAR AVIS BUDGET GROUP INC.
A AGILENT TECHNOLOGIES INC.
MSB MESABI TRUST
PESI PERMA-FIX ENVIRONMENTAL SERVICES INC.
HRTG HERITAGE INSURANCE HOLDINGS INC.
TATT TAT TECHNOLOGIES LTD.
IIIN INSTEEL INDUSTRIES INC.
SJT SAN JUAN BASIN ROYALTY TRUST
CHCI COMSTOCK HOLDING COMPANIES
SEZI SENZIME AB
ANAB ANAPTYSBIO INC.
TIGO MILLICOM INTERNATIONAL CELLULAR S.A.
FRAF FRANKLIN FINANCIAL SERVICES CO.
OVBC OHIO VALLEY BANC CORP
NEON NEONODE INC.
SMMT SUMMIT THERAPEUTICS INC
HTZ HERTZ GLOBAL HLDGS INC
MPTI M TRON INDUSTRIES INC
NUTX NUTEX HEALTH INC
ZBIO PROSHARES ULTRAPRO SHORT NASDAQ BIOTECHNOLOGY
VRM VROOM INC
- Blair Levin
BEAD Data Shows CMSCA Active in Many States
With all but four states having started and/or completed their prequalification process for eligibility for BEAD funding, there is new data showing high levels of participation by CMSCA and CHTR, with significant levels of participation by T and FBYR (to be acquired by VZ.) In this note we discuss that data and state of play as the states move forward and the Department of Commerce aims for a decision in about a month (which we think is likely to be delayed) for resolving how the BEAD should be...
- Pelham Smithers
- Jonathan Chaplin
Conflicting expectations in mobile and broadband
In our Broadband Trends report published this week, we show that bottom-up forecasts are well below our top-down forecast. The disconnect is all in Cable, and mostly in Comcast. We don’t have enough conviction in our top-down forecast to make a call on Comcast, particularly ahead of 1Q25 results where management has provided very clear context on trends, but we suspect results for the year won’t be as bad as feared. By contrast in our Wireless Trends report last week, we showed that our forecas...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.